Χώρα: Αυστραλία
Γλώσσα: Αγγλικά
Πηγή: Department of Health (Therapeutic Goods Administration)
risedronate sodium hemipentahydrate, Quantity: 173.4 mg
GM Pharma International Pty Ltd
Risedronate sodium hemipentahydrate
Tablet, film coated
Excipient Ingredients: lactose; hyprolose; hypromellose; crospovidone; titanium dioxide; magnesium stearate; colloidal anhydrous silica; macrogol 8000; monobasic sodium phosphate dihydrate; dibasic sodium phosphate; indigo carmine aluminium lake; monobasic sodium phosphate monohydrate
Oral
3, 4, 1, 2
Medicine Registered
(S4) Prescription Only Medicine
The treatment of osteoporosis,The treatment of glucocorticoid-induced osteoporosis,The preservation of bone-mineral density in patients on long term corticosteroid therapy
Visual Identification: Blue, round, biconvex coated tablet. Engraved "APO" on one side, "RIS" over "150" on the other side; Container Type: Blister Pack; Container Material: PVC/PVDC; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Licence status A
2012-03-08